Levels of the critical plasma clotting proteins von Willebrand Factor (VWF) and Factor VIII (FVIII) are widely variable in humans. High levels of VWF and FVIII confer an increased risk of thrombosis, while low levels are associated with bleeding. The wide range of quantitative variation in VWF has been well described, but the degree and nature of functional variation in VWF and its interaction with FVIII is less clear. We hypothesize that VWF is both quantitatively and qualitatively variable. There is some evidence that natural variation in the VWF molecule influences survival of VWF in circulation and/or may shift the nature of interactions with two of its key ligands, platelets and FVIII. We propose to study the natural variation of VWF in samples from 500 subjects from the General Lymphocyte and Plasma Repository (GLPR) by measuring attributes associated with the major hemostatic functions of VWF. We will evaluate parameters related to VWF survival, VWF platelet binding, VWF multimeric structure, and the interaction of VWF with FVIII. The known VWF modifiers ABO blood group and gender will be assessed and accounted for in the analysis. We will test a novel hypothesis that the FVIII/VWF ratio is normally variable, and pursue a new investigation into the influence of the blood group H antigen system on VWF molecular characteristics. The results of this study should lend new insights into the biology of VWF and FVIII, and may lead to the development of novel prognostic coagulation biomarkers for study in future clinical trials. Furthermore, this work could provide the foundation for the design or optimization of therapeutic agents in bleeding and clotting disorders.

Public Health Relevance

Levels of the critical clotting proteins von Willebrand Factor (VWF) and Factor VIII (FVIII) are widely variable in normal populations, in which high levels of either confer an increased risk of thrombosis and low levels are associated with bleeding. We propose to study the natural variation in molecular characteristics of VWF representative its major hemostatic functions. The results of this effort should not only broaden our understanding of hemostasis, but provide the foundation for the development of new laboratory tests and therapies for clotting and bleeding disorders

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL112680-01
Application #
8262582
Study Section
Special Emphasis Panel (ZHL1-CSR-P (F2))
Program Officer
Wagner, Elizabeth
Project Start
2012-04-15
Project End
2014-03-31
Budget Start
2012-04-15
Budget End
2013-03-31
Support Year
1
Fiscal Year
2012
Total Cost
$140,250
Indirect Cost
$65,250
Name
Puget Sound Blood Center
Department
Type
DUNS #
092881085
City
Seattle
State
WA
Country
United States
Zip Code
98104